Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers
Brendan Hagerty(Roswell Park Comprehensive Cancer Center), Christine Alewine(Dartmouth Psychiatric Research Center), Laura Bassel(Frederick National Laboratory for Cancer Research), T. Norene O’Sullivan(Frederick National Laboratory for Cancer Research), Nathan Pate(Sanofi (Mexico)), Theresa M. Guerin(Frederick National Laboratory for Cancer Research), Wendi Custer Lawrence(Frederick National Laboratory for Cancer Research), N. Keith Collins(Frederick National Laboratory for Cancer Research), Xianyu Zhang(Harbin Medical University), Serguei Kozlov(Frederick National Laboratory for Cancer Research), Jian Xu(University of California, Los Angeles)
Cited by 6
Related Papers
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
|Gastric Cancer|2014|615
Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis
|Molecular Carcinogenesis|2010|558
Drug resistance to targeted therapeutic strategies in non-small cell lung cancer
|Pharmacology & Therapeutics|2019|245
Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations
|Nature Genetics|2011|198
Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors
|Journal of Clinical Oncology|2017|177